Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study
ICP-332 is a novel, orally administered TYK2 inhibitor with high selectivity, intended for the treatment of immune inflammatory diseases such as atopic dermatitis, psoriatic arthritis, inflammatory bowel disease and lupus. This Phase I study assessed its safety, pharmacokinetics, pharmacodynamics, and food effect i...